Navigation Links
Cepheid Announces European Release of Xpert TV, a Next-Generation Molecular Test for Rapid and Accurate Identification of Trichomonas vaginalis Infections

SUNNYVALE, Calif., Sept. 3, 2014 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of Xpert® TV, an on-demand molecular test for rapid, accurate and reproducible identification of Trichomoniasis (TV) infections in both males and females. The test will be marketed as a CE-IVD product under the European Directive on In Vitro Diagnostic Medical Devices, bringing the total number of CE-IVD tests available to nineteen. Xpert TV runs on Cepheid's GeneXpert® System, the world's leading molecular diagnostic platform with more than 7,000 systems installed worldwide.

Trichomoniasis, the most common nonviral sexually transmitted disease, is caused by infection with the protozoan parasite Trichomonas vaginalis. The World Health organization has estimated that 160 million cases of infection are acquired worldwide each year.1 Most people who have the parasite cannot tell they are infected, only about 30% develop any symptoms.

"Xpert TV is the first nucleic acid amplification test to deliver TV results for male urine samples. It has been difficult to identify and contain TV infections in men because traditional diagnostic methods are much less sensitive than real-time PCR," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "Cepheid delivers the industry's most complete line of on-demand sexual health tests on a single molecular platform, enabling clinicians to deliver same day onsite patient consultation and treatment."

Identification of Trichomonas vaginalis infections is problematic. Organism viability, sensitivity issues with wet mount microscopy, and time delays for conclusive diagnosis from culture methods make detection of this asymptomatic infection a challenge. Xpert TV is a next generation solution. Each test cartridge includes three controls to ensure test integrity and performance. Sample adequacy control confirms that a patient sample is genuine and eliminates multiple daily examinations of the same samples.

"A decade ago Trichomonas vaginalis infections in men were virtually ignored. More current research has associated these infections with prostatitis and male factor infertility. In addition, trichomoniasis is emerging as a risk factor for sexual transmission of human immunodeficiency virus (HIV)," said David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "Increased vaginal and endocervical inflammation in women and urethral inflammation in men with trichomoniasis may contribute to enhanced HIV transmission. Trichomonas vaginalis also likely disrupts the urogenital epithelia and enhances HIV replication. Xpert TV provides accurate actionable results that clinicians need for optimal patient management."

Xpert TV begins shipping this month as a CE-IVD Mark product. For more information on Cepheid's GeneXpert Systems or complete menu of CE-IVD Xpert tests, visit

About Cepheid
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit



This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the performance, speed and accuracy of our products, including relative to competing products, the breadth and speed of test menu expansion, the results of clinical trials, and future medical practice dynamics.  Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: test performance in the field; utilization of our tests by clinicians; our ability to successfully develop new products; the completion of clinical trials for new products successfully and in a timely manner; uncertainties related to the United States FDA, European and other regulatory processes; the Company's ability to successfully introduce and sell products in clinical markets; the Company's research and development budget; unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying regulatory, political and market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

For Cepheid Media Inquiries:
Jared Tipton
Cepheid Corporate Communications

For Cepheid Investor Inquiries:
Jacquie Ross, CFA
Cepheid Investor Relations

SOURCE Cepheid
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Announces Executive Vice President Emerging Markets
3. Cepheid Reports Fourth Quarter And Full Year 2012 Results
4. Cepheid Schedules 2013 First Quarter Results Announcement And Webcast
5. Cepheid and American Lung Association Partner for Tuberculosis Awareness in U.S.
6. Cepheid Receives FDA Market Authorization for Xpert MTB/RIF
7. Cepheid Launches Mobile Community for Ride Against TB Campaign to Benefit the American Lung Association
8. Cepheid Highlights Promising Early Performance Of Its Cervical Cancer Test At AMP
9. Cepheid to Webcast Upcoming Financial Presentation
10. New Products, Price Movements, and Leadership Appointments - Research Report on Waters, Cognex, Fluidigm, Cepheid, and Bio-Rad
11. Cepheid Reports 2014 Second Quarter Results
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... Doctors who missed a ... to recognize the signs of mesothelioma and push for a diagnosis, especially in people ... website. Click here to read it now. , Researchers at Gifu ...
(Date:11/28/2015)... Diego, California (PRWEB) , ... November 28, 2015 ... ... medical image exchange technology and teleradiology services, has added Chris Hafey and Claude ... to exhibit at the Radiological Society of North America (RSNA) 2015 Annual Meeting ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Pixel Film ... customizable media panels to choose from, the possibilities are endless. Users have full control ... With the ProPanel: Pulse masking effects, users are sure to get heads to turn. ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... that they are handling security in light of the recent terrorist attacks in Paris, ... attempt to stop an attack from reaching U.S. soil. Especially around special events that ...
(Date:11/27/2015)... ... 27, 2015 , ... "When I was traveling, I was ... N.J. "Many people catch diseases simply from sitting on such dirty toilet seats. ... from germs." , He developed the patent-pending QUDRATECS to eliminate the need to ...
Breaking Medicine News(10 mins):